Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

1.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators.

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

2.

Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances.

Jaber BL, Schiller B, Burkart JM, Daoui R, Kraus MA, Lee Y, Miller BW, Teitelbaum I, Williams AW, Finkelstein FO; FREEDOM Study Group.

Clin J Am Soc Nephrol. 2011 May;6(5):1049-56. doi: 10.2215/CJN.10451110. Epub 2011 Mar 17.

3.

Effect of daily hemodialysis on depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study.

Jaber BL, Lee Y, Collins AJ, Hull AR, Kraus MA, McCarthy J, Miller BW, Spry L, Finkelstein FO; FREEDOM Study Group.

Am J Kidney Dis. 2010 Sep;56(3):531-9. doi: 10.1053/j.ajkd.2010.04.019. Epub 2010 Jul 29.

PMID:
20673601
4.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group.

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
5.

Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.

Stevens RB, Mercer DF, Grant WJ, Freifeld AG, Lane JT, Groggel GC, Rigley TH, Nielsen KJ, Henning ME, Skorupa JY, Skorupa AJ, Christensen KA, Sandoz JP, Kellogg AM, Langnas AN, Wrenshall LE.

Transplantation. 2008 May 27;85(10):1391-9. doi: 10.1097/TP.0b013e3181722fad.

PMID:
18497677
6.

Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant.

Shivaswamy V, Stevens RB, Zephier R, Zephier M, Sun J, Groggel G, Erickson J, Larsen J.

Transplantation. 2008 May 15;85(9):1270-6. doi: 10.1097/TP.0b013e31816de3F6.

7.

Obesity and hemodialysis vascular access failure.

Plumb TJ, Adelson AB, Groggel GC, Johanning JM, Lynch TG, Lund B.

Am J Kidney Dis. 2007 Sep;50(3):450-4.

PMID:
17720524
8.

New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines.

Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB.

Transplantation. 2005 Oct 15;80(7):945-52.

PMID:
16249743
9.

Elevated fasting pro-insulin levels as a marker for impaired function after pancreas transplantation.

Weide LG, Stratta RJ, Cushing K, Groggel G.

Transplant Proc. 1997 Feb-Mar;29(1-2):678. No abstract available.

PMID:
9123477
10.

Diabetic nephropathy.

Groggel GC.

Arch Fam Med. 1996 Oct;5(9):513-20; discussion 521. Review.

PMID:
8930222
11.
12.

Insulin-like growth factor-1 stimulates production of mesangial cell matrix components.

Schreiber BD, Hughes ML, Groggel GC.

Clin Nephrol. 1995 Jun;43(6):368-74.

PMID:
7554520
13.
14.
15.
16.

Proteoglycan and glycosaminoglycan synthesis by cultured rat mesangial cells.

Groggel GC, Hovingh P, Linker A.

J Cell Physiol. 1991 Jun;147(3):455-9.

PMID:
1906068
17.

Update on diabetic nephropathy in NIDDM.

Dere WH, Groggel GC.

Geriatrics. 1990 Jul;45(7):48-52, 55-6. Review.

PMID:
2194907
18.
19.

Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy.

Marinides GN, Groggel GC, Cohen AH, Border WA.

Kidney Int. 1990 Feb;37(2):749-57. Review.

PMID:
2407887
20.

Inhibition of rat mesangial cell growth by heparan sulfate.

Groggel GC, Marinides GN, Hovingh P, Hammond E, Linker A.

Am J Physiol. 1990 Feb;258(2 Pt 2):F259-65.

PMID:
2137981
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk